Trevi Therapeutics (TRVI) Change in Receivables (2018 - 2020)
Trevi Therapeutics (TRVI) posted quarterly Change in Receivables of -$433000.0 for Q1 2020, down 1173.53% year-over-year from $40334.2 in Q2 2019, and down 221.97% quarter-over-quarter from $355000.0 in Q4 2019.
Trevi Therapeutics (TRVI) Change in Receivables (2018 - 2020) Analysis & Trends
Trevi Therapeutics' Change in Receivables history runs 3 years deep, the most recent figure standing at -$433000.0 for Q1 2020.
- In Q1 2020, Change in Receivables fell 1173.53% year-over-year to -$433000.0; the TTM figure through Mar 2020 stood at -$25000.0 (down 130.12% YoY), while the FY2019 annual figure was $374000.0, up 177.04% from the prior year.
- Change in Receivables for Q1 2020 stood at -$433000.0, down from $355000.0 in the prior quarter.
- The five-year high for Change in Receivables was $355000.0 in Q4 2019, with the low at -$433000.0 in Q1 2020.
- The 3-year median for Change in Receivables is $20000.0 (2018), against an average of $8444.4.
- The sharpest annual moves came in 2019 and 2020: Change in Receivables surged 446.15% in 2019, then slumped 1173.53% in 2020.
- Trevi Therapeutics' Change in Receivables stood at $65000.0 in 2018, then soared by 446.15% to $355000.0 in 2019, then slumped by 221.97% to -$433000.0 in 2020.
- Business Quant data shows TRVI's Change in Receivables at -$433000.0 in Q1 2020, $355000.0 in Q4 2019, and -$48000.0 in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Trevi Therapeutics | 2.63 Bn | 2.63 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -433,000.00 |
| Mar 31, 2020 | -433,000.00 |
| Dec 31, 2019 | 355,000.00 |
| Dec 31, 2019 | 355,000.00 |
| Sep 30, 2019 | -48,000.00 |
| Sep 30, 2019 | -48,000.00 |
| Jun 30, 2019 | 101,000.00 |
| Jun 30, 2019 | 101,000.00 |
| Mar 31, 2019 | -34,000.00 |
| Mar 31, 2019 | -34,000.00 |
| Dec 31, 2018 | 65,000.00 |
| Dec 31, 2018 | 65,000.00 |
| Sep 30, 2018 | 32,000.00 |
| Sep 30, 2018 | 32,000.00 |
| Jun 30, 2018 | 20,000.00 |
| Jun 30, 2018 | 20,000.00 |
| Mar 31, 2018 | 18,000.00 |
| Mar 31, 2018 | 18,000.00 |